Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, Safety and Immunogenicity of Gardasil in Systemic Lupus Erythematosus

Trial Profile

Phase I, Safety and Immunogenicity of Gardasil in Systemic Lupus Erythematosus

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2018

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions
  • Acronyms GARDASIL
  • Most Recent Events

    • 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
    • 21 Apr 2017 Status changed from active, no longer recruiting to completed, according to the results published in the Vaccine.
    • 09 Apr 2017 Results evaluating the safety and immunogenicity published in the Vaccine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top